Warr D, Willan A, Fine S, Wilson K, Davis A, Erlichman C, Rusthoven J, Lofters W, Osoba D, Laberge F
Department of Medicine, University of Toronto-Princess Margaret Hospital, Ontario, Canada.
J Natl Cancer Inst. 1991 Aug 21;83(16):1169-73. doi: 10.1093/jnci/83.16.1169.
Trials of selective 5-hydroxytryptamine3 receptor antagonists have shown excellent antiemetic activity for chemotherapy containing cisplatin when compared with high-dose metoclopramide. There is little information about the efficacy of these new agents for chemotherapy other than for high-dose cisplatin. We performed a double-blind, randomized trial comparing a single dose of the 5-hydroxytryptamine3 receptor antagonist granisetron (BRL 43694A) as a single intravenous dose with dexamethasone plus prochlorperazine in 152 patients receiving their first course of moderately emetogenic chemotherapy (mainly doxorubicin- and cyclophosphamide-containing combinations). During the first 24 hours, there was a statistically significant advantage for the granisetron group in terms of the prevention of both nausea and emesis. There was no difference in the frequency of reported adverse events. We conclude that granisetron is more effective than dexamethasone plus prochlorperazine in patients who are receiving moderately emetogenic cytotoxic agents.
与大剂量甲氧氯普胺相比，选择性5-羟色胺3受体拮抗剂的试验表明，在含顺铂的化疗中具有出色的止吐活性。除了大剂量顺铂化疗外，关于这些新药对其他化疗的疗效信息甚少。我们进行了一项双盲随机试验，将152例接受第一疗程中度致吐性化疗（主要是含阿霉素和环磷酰胺的联合化疗）的患者分为两组，一组静脉注射单剂量的5-羟色胺3受体拮抗剂格拉司琼（BRL 43694A），另一组静脉注射地塞米松加丙氯拉嗪。在最初的24小时内，格拉司琼组在预防恶心和呕吐方面具有统计学上的显著优势。报告的不良事件发生率没有差异。我们得出结论，在接受中度致吐性细胞毒性药物治疗的患者中，格拉司琼比地塞米松加丙氯拉嗪更有效。
